Pharma violates own marketing regulations, Swedish study alleges

19 February 2015
abpi-big

A new report from Lund University in Sweden claims to show how the pharmaceutical industry, time and again, violates regulations on the marketing of drugs. The study has been published in the journal PLOS Medicine.

In order to avoid unethical marketing, the pharmaceutical industry has a well-established system of self-regulation. There are individual national systems, but they are very similar in many European countries.

An interdisciplinary research group comprising researchers in social science and medicine have investigated judgments from the self-regulation bodies in the UK and Sweden over the years 2004 to 2012. The study revealed 597 and 536 cases respectively of marketing that violated the industry’s own regulations. This means that unethical marketing of pharmaceutical drugs happens on average more than once a week in both the UK and Sweden, the study suggests.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical